Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease
NCT ID: NCT04440891
Last Updated: 2023-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2019-10-03
2021-11-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
NCT06088121
TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory
NCT04294888
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
NCT06538311
Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
NCT00753662
The Effect of rTMS Treatment on Alzheimer's and Sleep Quality
NCT01894620
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TMS-Stimulation with X-Torp task
TMS with VR 1 experimental arm
TMS stimulation with X-Torp task
TMS-Stimulation with X-Torp task
TMS-Stimulation with MindMotion Go
TMS with VR 2 experimental arm
TMS-Stimulation with MindMotion Go
TMS-Stimulation with MindMotion Go
TMS-Sham with X-Torp task
TMS sham control with VR 1
TMS-Sham with X-Torp task
TMS-Sham with X-Torp task
TMS-Sham with MindMotion Go
TMS sham control with sham VR 2
TMS-Sham with MindMotion Go
TMS-Sham with MindMotion Go
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TMS stimulation with X-Torp task
TMS-Stimulation with X-Torp task
TMS-Stimulation with MindMotion Go
TMS-Stimulation with MindMotion Go
TMS-Sham with X-Torp task
TMS-Sham with X-Torp task
TMS-Sham with MindMotion Go
TMS-Sham with MindMotion Go
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able and willing to give informed consent
* Probable AD consistent with NIA/AA criteria
* Modified Hachinski Ischemia Scale (MHIS) score of \<= 4
* Geriatric Depression Scale (GDS) score of \<= 6
* Mini Mental State Exam (MMSE) score 18-26. The MMSE adjusted scoring instructions may be followed for screening patients as applicable.
Exclusion Criteria
* Visual impairments
* Mobility limitations
* Cognition-enhancing medication unless on a stable dosage for at least 3 months before the start of the trial.
* History of epilepsy or seizure disorder
* History of psychosis
* Current thoughts of suicidal ideation or self-harm as assessed by the Columbia-Suicide severity rating scale score
* Progressive neurological disorder or focal signs of abnormality on neurological exam as conducted by a neurologist (other than current diagnosis of AD)
* Tinnitus
* Metal implants (excluding dental fillings)
* Possible pregnancy
* Substance use disorder within the past six months
* Have other mental or physical conditions that are inappropriate for study participation at PI's or delegated sub investigator's discretion.
* Intake of one or a combination of the drugs that may due to their significant seizure threshold lowering potential
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ali Rezai
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ali Rezai
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc Haut, PhD
Role: STUDY_CHAIR
Rockefeller Neuroscience Institute
Victor Finomore, PhD
Role: STUDY_DIRECTOR
Rockefeller Neuroscience Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West Virginia University Rockefeller Neuroscience Institute
Morgantown, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1904522298
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.